CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses, announced its participation in the Piper Sandler 36th Annual Healthcare Conference. CEO Rachel Leheny, Ph.D., will present on December 4, 2024, at 9:10 a.m. ET. The presentation will be available via live webcast on CalciMedica's IR website, with a replay accessible for 90 days following the event.
CalciMedica (Nasdaq: CALC), una azienda biofarmaceutica in fase clinica che sviluppa terapie per l'inibizione dei canali CRAC per malattie infiammatorie e immunologiche, ha annunciato la sua partecipazione alla 36ª Conferenza Annuale sulla Salute di Piper Sandler. La CEO Rachel Leheny, Ph.D., presenterà il 4 dicembre 2024, alle 9:10 ET. La presentazione sarà disponibile tramite webcast dal vivo sul sito delle relazioni con gli investitori di CalciMedica, con una registrazione accessibile per 90 giorni dopo l'evento.
CalciMedica (Nasdaq: CALC), una empresa biofarmacéutica en etapa clínica que desarrolla terapias de inhibición de canales CRAC para enfermedades inflamatorias e inmunológicas, anunció su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La CEO Rachel Leheny, Ph.D., presentará el 4 de diciembre de 2024 a las 9:10 a.m. ET. La presentación estará disponible a través de una transmisión web en vivo en el sitio de IR de CalciMedica, con una repetición accesible durante 90 días después del evento.
CalciMedica (Nasdaq: CALC)는 염증 및 면역 질환을 위한 CRAC 채널 억제 요법을 개발하는 임상 단계의 생물의약품 회사로, Piper Sandler 제36회 연례 의료 회의에 참여한다고 발표했습니다. CEO인 Rachel Leheny 박사는 2024년 12월 4일 오전 9시 10분(ET)에 발표할 예정입니다. 발표 내용은 CalciMedica의 IR 웹사이트에서 생중계로 제공되며, 행사 후 90일 동안 다시 볼 수 있습니다.
CalciMedica (Nasdaq: CALC), une entreprise biopharmaceutique en phase clinique développant des thérapies d'inhibition des canaux CRAC pour les maladies inflammatoires et immunologiques, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. La PDG Rachel Leheny, Ph.D., présentera le 4 décembre 2024 à 9h10 (ET). La présentation sera disponible en direct par webcast sur le site des relations investisseurs de CalciMedica, avec une rediffusion accessible pendant 90 jours après l'événement.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das therapeutische Maßnahmen zur Hemmung der CRAC-Kanäle zur Behandlung von entzündlichen und immunologischen Erkrankungen entwickelt, hat seine Teilnahme an der 36. jährlichen Gesundheitskonferenz von Piper Sandler bekannt gegeben. CEO Rachel Leheny, Ph.D., wird am 4. Dezember 2024 um 9:10 Uhr ET präsentieren. Die Präsentation wird live über das IR-Portal von CalciMedica übertragen, und eine Aufzeichnung ist 90 Tage nach der Veranstaltung verfügbar.
- None.
- None.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced topline data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney disease (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302312144.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch CalciMedica's (CALC) Piper Sandler Conference presentation?
What type of therapies is CalciMedica (CALC) developing?
